Navigation Links
ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing

ADDISON, Texas, Jan. 19, 2011 /PRNewswire/ -- ULURU Inc. (NYSE Alternext: ULU) announced today that it has signed a Binding Letter of Intent ("Agreement") with Exciton Technologies Inc. ("Exciton") to develop and market a product that will combine Altrazeal® with Exciton's proprietary exSALT™ Antimicrobial Technology.

Under the terms of the agreement ULURU will be granted a worldwide license, excluding China, to market the Altrazeal® exSALT™ product. Exciton will be responsible for conducting the necessary product testing, filing a 510(k) application with the FDA and interacting with the FDA to secure product approval. ULURU will be responsible for product approval in International markets including gaining CE Mark approval. ULURU will pay Exciton to prepare and prosecute the 510(k) application, milestone payments on the attainment of sales targets and a royalty based on product sales. The parties have agreed to negotiate a final agreement that will supersede the Binding Letter of Intent.

Exciton has developed a unique silver technology which has equivalent or greater antimicrobial efficacy at a markedly lower silver concentration compared to other currently marketed silver products. Preliminary testing has been conducted on the combination of Altrazeal® and exSALT™ in an in-vitro log reduction assay, which meets draft guidance from the FDA for testing of medical devices containing an antimicrobial agent. This testing has been performed against Staphylococcus aureus, one of the more resistant bacterial strains. The performance of Altrazeal® exSALT™ was compared to five market leading silver containing products. Of the five commercial products tested only two products passed this antimicrobial efficacy test and both of these products contained significantly more silver (3.75 and 7.50 times more silver) than Altrazeal® exSALT™.

Commenting on the Agreement, Rod Precht, President of Exciton Technologies Inc., stated, "We are delighted to be working with ULURU to develop a product containing two patented technologies which appear to work synergistically to potentially provide significant clinical advantages. The initial in-vitro testing clearly indicates that Altrazeal® exSALT™ has superior properties to the market leading products in this market category."

It is anticipated that a 510(k) application will be filed with the FDA in approximately 90 days. Assuming no extended delays in FDA review, approval of Altrazeal® exSALT™ could occur as early as the third quarter of 2011. The antimicrobial segment of the North American advanced wound care market is projected to grow in the next 5 years to be in excess of $750 million with annual growth rates above 15%.

Commenting on the Agreement, Kerry P. Gray, President and CEO of ULURU Inc., stated, "Combining these two leading technologies offers the potential for a dominant product in the antimicrobial dressing market. The superior antimicrobial activity at a significantly lower silver concentration is an outstanding product benefit. As we assessed our silver product strategy, given the favorable product profile of Altrazeal® exSALT™, it became obvious that this was our best course of action compared with pursuing our prior silver product application. This revised strategy also addresses questions previously raised by the FDA."

About ULURU Inc.:ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at For further information about Altrazeal®, please visit

About Exciton Technologies Inc.:Exciton Technologies Inc. is a Canadian, privately-held advanced materials research and development company focused on the creation of technologies for preventing and controlling infection. The company has a valuable portfolio of patentable platform technologies and FDA cleared wound care products based on the antimicrobial properties of silver. For more information about Exciton Technologies Inc., please visit our website at

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended including the antimicrobial efficacy of Altrazeal® exSALT, the market potential of Altrazeal® exSALT, the size of the current and potential market for Altrazeal® exSALT, the negotiation of the definitive agreement that will supersede the Binding Letter of Intent, the timing of filing of an application with the FDA and the timing of any approval of such filing, and the favorable product profile of Altrazeal® exSALT. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.Contact: CompanyKerry P. GrayPresident & CEOTerry K. WallbergVice President & CFO(214) 905-5145

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. to Raise $500,000 in Registered Direct Offering
2. ULURU Inc. Reports Third Quarter 2010 Financial Results
3. ULURU Inc. Provides Altrazeal® Clinical Update
4. ULURU Inc. Announces Conference Call
5. ULURU Inc. Reports Second Quarter 2010 Financial Results
6. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
7. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
9. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
10. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
11. Pharmasset Announces Proposed Public Offering of Common Stock
Post Your Comments:
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
Breaking Medicine Technology:
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward joins ... other leading institutions in announcing the launch of the Leadership Circle , ... animals are raised for food. , Founding members of the Leadership Circle also ...
Breaking Medicine News(10 mins):